Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

HHS secures 500,000 doses of remdesivir

Caitlin Owens, author of Vitals

White House coronavirus task force coordinator Deborah Birx and HHS Sec. Alex Azar

The Trump administration has secured 500,000 doses of remdesivir, the first drug shown to be effective at treating hospitalized coronavirus patients, ensuring these doses will be for U.S. use.

Between the lines: The administration is not directly purchasing the drug, but it will use coronavirus hospitalization data to determine how to allocate it by state, and state health departments will decide which hospitals will get the drug.

Go deeper

Caitlin Owens, author of Vitals
Sep 23, 2020 - Health

The FDA plans to toughen coronavirus vaccine standards

President Trump and FDA commissioner Stephen Hahn. Photo: Pete Marovich/Getty Images

The Food and Drug Administration plans to toughen the requirements for a coronavirus vaccine emergency authorization, which would make it more difficult for one to be ready by the election, the Washington Post reported Tuesday.

Why it matters: Public skepticism of an eventual vaccine keeps increasing as President Trump keeps making promises that are at odds with members of his own administration.

Go deeper (1 min. read)Arrow
Jacob Knutson
Oct 6, 2020 - Politics & Policy

Top vaccine whistleblower Rick Bright resigns from government

Richard Bright, former director of the Biomedical Advanced Research and Development Authority, testifying before Congress in May. Photo: Greg Nash-Pool/Getty Images

The senior vaccine scientist who said in a whistleblower complaint last May that he was demoted for political reasons resigned from his position at the Department of Health and Human Services on Tuesday, the New York Times reports.

Why it matters: Rick Bright, who was chief of the Biomedical Advanced Research and Development Authority (BARDA), told Congress in May he believes he was demoted after trying to limit the use of chloroquine and hydroxychloroquine to treat the coronavirus.

Go deeper (1 min. read)Arrow
Maria Arias
Oct 6, 2020 - Technology

Facebook and Twitter take action against misleading Trump post

Photo: Win McNamee/Getty Images

Facebook on Tuesday removed a post from President Trump in which he falsely claimed that COVID-19 is less deadly "in most populations" than the flu. Twitter labeled the tweet for violating its rules about "spreading misleading and potentially harmful information," but left it up because it may be "in the public's interest."

Why it matters: Facebook has been criticized for not removing posts that violate community guidelines in a timely manner, yet the company sprung to action when Trump posted misinformation about the virus that "could contribute to imminent physical harm." Twitter took action about 30 minutes later.

Go deeper (1 min. read)Arrow